Crestor

Jump to

AstraZeneca flags falling profit while awaits key drug data

The British pharmaceuticals group hopes that 2017 will be the earnings trough, but its recovery hinges on the success of new medicines and results from a clinical trial of a combination of two lung cancer drugs, which investors view as risky.
Q3 results: Five trends to watch out from Indian drugmakers

Analysts predict Q3 to be a tough quarter with revenue growth moderating to 11.7 percent in October-December period compared to 18.4 percent compounded annual growth rate (CAGR) over last 10 years
Biosimilars to lead growth; generics to be a small part: Biocon

Biotechnology major Biocon reported 19.8 percent rise in revenue to Rs 796.2 crore year-on-year and margins grew to 25.2 percent from 21.2 percent in the second quarter of FY17. The company‘s standalones sale grew 17 percent in Q2.
As AstraZeneca's Crestor goes off patent, generic cos to jump in

The cardiac drug, Crestor, is said to be one of the biggest launches for USFDA this year and the market size for the drug is about USD 3 billion, reports Ekta Batra of CNBC-TV18. The drug goes off patent tomorrow in the US.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Crestor

AstraZeneca flags falling profit while awaits key drug data

Q3 results: Five trends to watch out from Indian drugmakers

Biosimilars to lead growth; generics to be a small part: Biocon

As AstraZeneca's Crestor goes off patent, generic cos to jump in